SUMMIT - Neratinib Basket Study (Multi-Institute, Nature 2018): MSK-IMPACT sequencing of 86 patients with HER2- and HER3-mutant cancers

Description: This dataset contains summary data visualizations and clinical data from a broad sampling of HER2- and HER3-mutant tumors. The data was generated utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK), mutation count, information about mutated genes, Amplification Status, Best objective response rate, Bubble Group Central, Clonality, Cohort, Coverage, Criteria, Data, Domain, Duration of Therapy Days, ER_PR, Gene, IMPACT, and Local Test MSI Status. The dataset includes copy-number segment data downloadable as .tar files and viewable via the Integrative Genomics Viewer.

Subject of Study

Subject(s)

OncoTree Cancer Type(s)

Ampullary Carcinoma
Biliary Tract
Bladder/Urinary Tract
Bladder Urothelial Carcinoma
Bladder Squamous Cell Carcinoma
Cervical Adenoid Cystic Carcinoma
Renal Clear Cell Carcinoma
Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Cholangiocarcinoma
Colon Adenocarcinoma
Colorectal Adenocarcinoma
Cancer of Unknown Primary
Duodenal Adenocarcinoma
Endocervical Adenocarcinoma
Esophagogastric Adenocarcinoma
Extramammary Paget Disease
Esophageal Adenocarcinoma
Gallbladder Cancer
Adenocarcinoma of the Gastroesophageal Junction
High-Grade Serous Ovarian Cancer
Inflammatory Breast Cancer
Breast Invasive Ductal Carcinoma
Intrahepatic Cholangiocarcinoma
Breast Invasive Lobular Carcinoma
Lung Adenocarcinoma
Large Cell Neuroendocrine Carcinoma
Breast Mixed Ductal and Lobular Carcinoma
Non-Small Cell Lung Cancer
Ovary/Fallopian Tube
Ovarian Epithelial Tumor
Pancreatic Adenocarcinoma
Pleomorphic Liposarcoma
Renal Cell Carcinoma
Small Bowel Cancer
Small Bowel Well-Differentiated Neuroendocrine Tumor
Salivary Duct Carcinoma
Cutaneous Melanoma
Serous Ovarian Cancer
Signet Ring Cell Carcinoma of the Stomach
Stomach Adenocarcinoma
Urethral Adenocarcinoma
Uterine Clear Cell Carcinoma
Endometrial Carcinoma
Urethral Urothelial Carcinoma
Uterine Endometrioid Carcinoma
Urachal Carcinoma
Uterine Serous Carcinoma/Uterine Papillary Serous Carcinoma

Access via cBioPortal
Access Restrictions: Free to All
Access Instructions: This cBioPortal for Cancer Genomics dataset is publicly available for viewing online as a table. The data is also available for download in its entirety as a tarball. Some features are only available by logging in with a Google or Microsoft account. These features include storing your virtual studies and groups which allows you to access your studies and groups from any computer, and to allow cBioPortal to remember your study view charts preferences for each study (i.e. order of the charts, type of charts and visibility). Login is optional and not required to access any of the other features of cBioPortal.
Associated Publications: Hyman D, Piha-Paul S, Won H, et al. HER kinase inhibition in patients with HER2-and HER3-mutant cancers. Nature. 2018; 554(7691):189-194.
Data Type: Genomic
Software Used: OncoTree
Open-source ontology that was developed at Memorial Sloan Kettering Cancer Center (MSK) for standardizing cancer type diagnosis from a clinical perspective by assigning each diagnosis a unique OncoTree code.
Dataset Format(s): Plain Text, TAR
Data Tool(s): MSK-IMPACT
Dataset Size: 143 KB

Other Resources: Clinicaltrials.gov registry
Open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors.
Data Catalog Record Updated: 2021-10-28